Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALAN SR vs AMVAZ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to negative inotropic, chronotropic, and dromotropic effects, and vasodilation.
AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.
Essential hypertension,Chronic stable angina,Variant (Prinzmetal) angina,Supraventricular tachyarrhythmias (e.g., atrial fibrillation, atrial flutter, PSVT),Off-label: migraine prophylaxis, cluster headache,Off-label: hypertrophic cardiomyopathy
FDA-approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Oral: 180–240 mg once daily; maximum 480 mg/day.
Intravenous: 500 mg every 6 hours.
Terminal elimination half-life is 6-12 hours (average ~8 hours) after single oral dose; may increase to 12-16 hours with chronic dosing due to saturable hepatic metabolism; clinical context: requires dosing adjustments in hepatic impairment.
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 30 hours) requiring dose adjustment.
Primarily hepatic via CYP3A4; first-pass metabolism; major metabolite norverapamil retains 20% activity.
AMVAZ is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes involved.
Approximately 70% of the dose is excreted as metabolites in the urine; 3-4% as unchanged drug; 25% eliminated in feces via biliary excretion.
Primarily renal excretion of unchanged drug (60-70%) and metabolites (10-20%); biliary/fecal excretion accounts for 15-25%.
Approximately 90% bound to plasma proteins (mainly albumin).
98% bound to albumin primarily, with minor binding to alpha-1-acid glycoprotein.
3.5 L/kg; indicates extensive tissue binding and distribution beyond plasma volume.
0.2-0.3 L/kg, indicating minimal extravascular distribution and confinement to plasma volume.
Oral (sustained-release): 40-60% due to first-pass metabolism; immediate-release: 70-80% when fasting but reduced to ~50% with food.
Oral bioavailability is 85-95%; reduced to 60-70% when taken with high-fat meals.
Cr Cl <30 m L/min: reduce dose by 50–75% of normal; initiate at lower end of dosing range.
Cr Cl 30-50 m L/min: 250 mg every 6 hours; Cr Cl 15-29 m L/min: 250 mg every 12 hours; Cr Cl <15 m L/min: 250 mg every 24 hours; hemodialysis: 250 mg after dialysis.
Child-Pugh A: no adjustment; Child-Pugh B or C: reduce dose by 50% and monitor.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50%.
Not FDA-approved for children; limited data: 4–8 mg/kg/day divided twice daily (immediate-release form only).
10 mg/kg IV every 6 hours; maximum 500 mg per dose.
Initiate at 120 mg once daily; titrate slowly due to increased bioavailability and prolonged half-life.
Consider renal function; start at lower end of dosing range due to age-related decreased renal clearance.
None
None
Heart failure: may exacerbate due to negative inotropic effects,Hypotension,Bradycardia/AV block: avoid in sick sinus syndrome or high-grade AV block without pacemaker,Hepatic impairment: reduce dose,Concomitant beta-blockers: increased risk of bradycardia and heart failure,Digoxin toxicity: verapamil increases digoxin levels
Infusion-related reactions (IRRs): premedicate and monitor during infusion; interrupt or discontinue if severe.,Interstitial lung disease (ILD)/pneumonitis: monitor for new or worsening respiratory symptoms; withhold or permanently discontinue.,Dermatologic adverse reactions (rash, dry skin, pruritus): manage with topical corticosteroids, emollients, and oral antihistamines; consider dose modification.,Ocular toxicity: monitor for keratitis, uveitis; refer to ophthalmology if symptoms develop.,Embryo-fetal toxicity: can cause fetal harm; advise effective contraception.
Severe left ventricular dysfunction (ejection fraction <30%),Cardiogenic shock,Sick sinus syndrome or 2nd/3rd degree AV block (except with functioning pacemaker),Atrial fibrillation/flutter with accessory bypass tract (e.g., WPW),Hypersensitivity to verapamil
None
Avoid grapefruit and grapefruit juice as they can increase verapamil levels. Limit alcohol consumption as it may enhance hypotensive effects. High-fat meals may delay absorption but not significantly affect overall bioavailability.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing amiodarone levels and risk of toxicity. Limit alcohol consumption due to potential hepatotoxicity. High-fat meals may increase absorption; take consistently with or without food.
Verapamil (CALAN SR) is classified as FDA Pregnancy Category C. First trimester: Animal studies have shown embryotoxicity and fetotoxicity, but no well-controlled human studies exist. Risk cannot be ruled out. Second/third trimesters: May cause fetal bradycardia, hypotension, and impaired placental perfusion. Avoid use in pregnancy unless benefit outweighs risk.
No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters: no known fetal harm.
Verapamil is excreted into breast milk with a milk-to-plasma ratio (M/P) of approximately 0.23 to 0.94 (mean~0.6). Infant dose is low (<5% maternal weight-adjusted dose). No adverse effects reported in breastfed infants. Consider monitoring infant for bradycardia, hypotension, and constipation.
No data on excretion in human milk; M/P ratio unknown. Caution recommended; benefits of breastfeeding should be weighed against potential risk to infant.
Pregnancy may increase verapamil clearance due to expanded plasma volume and enhanced renal/hepatic metabolism. Dose adjustments may be needed to maintain therapeutic effect; monitor clinical response and consider therapeutic drug monitoring. Start at lower doses and titrate cautiously.
No specific dose adjustments required in pregnancy; pharmacokinetic changes not well-characterized. Use lowest effective dose and monitor clinical response.
CALAN SR (verapamil sustained-release) is a non-dihydropyridine calcium channel blocker used for hypertension and angina. Avoid use in patients with pre-existing severe left ventricular dysfunction, hypotension, or sick sinus syndrome without a pacemaker. Caution with concomitant beta-blockers due to risk of bradycardia or heart block. Verapamil is a potent CYP3A4 inhibitor; monitor for increased levels of statins, cyclosporine, and other CYP3A4 substrates.
AMVAZ (amiodarone) has a long half-life (up to 107 days) and can cause thyroid, pulmonary, hepatic, and skin toxicity. Monitor thyroid function (TSH, T3, T4), liver enzymes (ALT, AST), and perform baseline pulmonary function tests and chest X-ray. Corneal microdeposits are common and may cause visual halos; usually reversible. Administer loading dose to achieve therapeutic effect more quickly. Avoid use with grapefruit juice as it increases drug levels.
Take exactly as prescribed; do not crush or chew the extended-release tablet.,Can be taken with or without food, but avoid grapefruit and grapefruit juice.,Do not suddenly stop taking this medication; abrupt withdrawal may worsen chest pain.,Report symptoms of heart failure such as shortness of breath, swelling of ankles/feet.,May cause dizziness or fatigue; avoid driving until you know how it affects you.,Constipation is common; maintain adequate fluid and fiber intake.
Take AMVAZ exactly as prescribed; do not stop without consulting your doctor.,Avoid grapefruit and grapefruit juice while taking this medication.,Report any new or worsening shortness of breath, cough, chest pain, or palpitations immediately.,Notify your doctor if you experience vision changes, yellowing of skin/eyes, dark urine, or unusual fatigue.,Use effective contraception during treatment and for at least 6 months after stopping.,Avoid excessive sun exposure; use sunscreen and protective clothing due to risk of skin discoloration and photosensitivity.,Do not take over-the-counter medications or herbal supplements without checking with your doctor.,Regular blood tests and eye exams are necessary while on this medication.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALAN SR vs AMVAZ, answered by our medical review team.
CALAN SR is a Calcium Channel Blocker that works by Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to negative inotropic, chronotropic, and dromotropic effects, and vasodilation.. AMVAZ is a Calcium Channel Blocker that works by AMVAZ (amivantamab-vmjw) is a bispecific monoclonal antibody that targets the extracellular domains of epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It inhibits ligand binding, receptor activation, and downstream signaling, leading to antibody-dependent cellular cytotoxicity and tumor cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALAN SR and AMVAZ depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALAN SR is: Oral: 180–240 mg once daily; maximum 480 mg/day.. The standard adult dose of AMVAZ is: Intravenous: 500 mg every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALAN SR and AMVAZ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALAN SR is classified as Category C. Verapamil (CALAN SR) is classified as FDA Pregnancy Category C. First trimester: Animal studies have shown embryotoxicity and fetotoxicity, but no well-controlled human studies exi. AMVAZ is classified as Category C. No human data available; in animal studies, no teratogenicity observed at clinically relevant doses. First trimester: data insufficient to assess risk. Second and third trimesters:. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.